The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Boehringer, Eureka Therapeutics to develop new antibodies for cancer treatment.....           Baxter BioScience submits MAA in Europe for IGSC 20% to treat primary immunodeficiency.....           Wockhardt gets FDA QIDP status for new pneumonia drug WCK 4873.....           Strides Arcolab to buy Aspen's generic drugs business in Australia for $300m.....           Aura Biosciences gets FDA orphan disease designation for AU-011 to treat uveal melanoma.....           Kite Pharma begins dosing in Phase I/II trial of KTE-C19 to treat refractory aggressive NHL.....           FDA accepts Tris Pharma's NDA for Dyanavel XR to treat ADHD.....           German cost watchdogs look askance at uniQure's $1.4M gene therapy.....           Novo, Baxter spar over hemophilia patent amid ITC probe.....           Aspen unloads $301M worth of meds to fuel expansion abroad.....           Report: Cadila next in line for injectables bulk-up as it nears deal for Claris.....           CVS Health gets more drug pricing clout with $12B deal for Omnicare.....           Endo sews up $9.2B financing for Par Pharma buyout.....           Eisai introduces in-house developed thyroid cancer drug Lenvima in Japan.....           FDA grants orphan drug status for Alnylam's Revusiran to treat TTR-mediated amyloidosis.....           Bristol-Myers gets amended FDA breakthrough therapy status for daclatasvir-based HCV regimen.....           Faron, China Medical System to develop traumakine to treat ARDS.....           Biomay to use VTU Pichia strains to produce recombinant allergens.....           Discovery Labs begins patient enrollment in Phase IIa dose expansion trial of Aerosurf.....           ImmunoClin to offer CRO Services for Part II of Phase I crotoxin trial for Celtic Biotech.....           SignalRx gets STTR grant from NIH to develop dual PI3 kinase/bromodomain inhibitors as anticancer agents.....           PlasmaTech's lead product candidates get FDA orphan drug and rare pediatric disease designations.....           Precision Biologics completes patient accrual to ensituximab Phase II colorectal cancer trial.....           Aphios gets US patent for Alzheimer?s disease treatment.....           Moberg Pharma partner Menarini Asia-Pacific introduces Kerasal Nail in china.....           vTv Therapeutics begins Phase III trial of azeliragon to treat mild Alzheimer's disease.....           The root of Orexigen's Contrave data blunder: CEO's 'I have to see it' choice.....           Report: Valeant in talks to buy Egypt's Amoun for up to $800M.....           Should Pfizer snap up GSK? Well, a megadeal could speed up a split.....           J&J promises new uses for old meds to keep pharma sales flying high.....           Hep C landscape shifts again as BMS combo nabs breakthrough tag.....           ProPublica: Safety questions over GSK's Advair linger after years on the asthma throne.....           Takeda to distribute Kaketsuken's seasonal influenza vaccine in Japan.....           Genmab, BioNTech to develop bispecific antibody products using DuoBody technology.....           Sarepta to submit rolling NDA for eteplirsen to treat DMD.....           Janssen, Achillion to develop new oral regimens to treat hepatitis C virus.....           vTv Therapeutics begins Phase III trial of azeliragon to treat mild Alzheimer's disease.....           GlycoMimetics begins Phase I/II trial of GMI-1271 to treat AML.....           OCTC, Bryla CMC-Reg Consulting to deliver CMC services for pharmaceutical industry.....           Melinta's phase III trial shows significant burden of obesity on patients' recovery from ABSSSI.....           Alcyone Lifesciences, DNAtrix enter clinical collaboration for brain cancer.....           Emergent signs long-term manufacturing deal with Prometic Life Sciences.....           Inergetics, Muscle Maker Grill introduce new booster supplements product line.....           Sunovion reports positive results for Latuda in first placebo-controlled trial in MDD patients.....           Actavis introduces Namzaric in US to treat moderate to severe Alzheimer's disease.....           Merck KGaA stumbles in Q1 as MS injectable Rebif falls to oral rivals.....           J&J nears $7.5M deal in Risperdal case that could have cost $1.2B.....           Lechleiter takes up Big Pharma's torch to 'debunk' negative myths.....           Can Baxalta deliver on its big growth promises? Baxter says yes.....           Actavis wins more hearts on Wall Street as 'top 4' Morgan Stanley pick.....           AstraZeneca to build $285m biologics manufacturing facility in Sweden.....           Actavis introduces Namzaric in US to treat moderate to severe Alzheimer's disease.....           Ablynx, Genzyme collaborate on multiple sclerosis research project.....           AbGenomics begins Phase-Ib/IIa trial of neihulizumab to treat steroid refractory aGvHD.....           RadioMedix, Areva Med to develop new treatment against NETs.....           Kura Oncology begins dosing in Phase II tipifarnib trial to treat tumors with HRAS mutations.....           Corbus gets FDA nod to begin Phase II trial of Resunab to treat cystic fibrosis.....           Boehringer acquires Pharmaxis' Phase 1 anti-inflammatory drug candidate.....           Endo scoops up Par Pharma for $8B to gain ground in injectables.....           AstraZeneca, betting on biologics, will build a $285M facility in Sweden.....           FDA's SGLT2 warning bad news for AZ, J&J and Lilly--but could be a boon for Merck.....           Heavyweight investors sock big bucks into Valeant while others sell down.....           Hep C patient sues Blue Cross for blocking access to Harvoni.....           Relax, J&J--Eliquis may be surging, but Xarelto's safe for now.....           Perrigo will talk tie-up if the price is right, CEO says--but Mylan has a ways to go.....           FDA approves Baxter's additional manufacturing site for sodium chloride injection in US.....           Abbvie gets FDA orphan drug status for Humira to treat Hidradenitis Suppurativa.....           Alnylam seeks MHRA approval for ALN-AAT Phase I/II trial to treat alpha-1 liver disease.....           Pernix's Treximet gets FDA approval to treat migraine in pediatric patients.....           Immunomedics gets FDA fast track status for lung cancer drug sacituzumab govitecan.....           Zambon and Newron launch Xadago in Germany to treat mid- to late-stage Parkinson?s disease.....           Health Canada approves new vial size of CSL Behring's Berinert to treat hereditary angioedema.....           TissueGene enters SPA agreement with FDA for Phase III trial of Invossa to treat osteoarthritis of the knee.....           SanBio gets key patent from USPTO for new treatment for chronic stroke.....           Roche reports positive interim results from Phase II trial of MPDL3280A.....           MTTI gets expanded patent approval for 99mTc-Duramycin technology to target programmed cell death.....           Amgen reports positive Phase II trial data for AMG 334 for prevention of episodic migraine.....           Iroko launches Zorvolex in Lebanon for acute and chronic pain.....           Merck scores victory in India patent battle over top diabetes meds.....           New CEO Weber deals with Takeda's loss and promises brighter future.....           Eisai predicts long-awaited operating profit rise for fiscal 2015.....           AbbVie nabs FDA's orphan drug tag for Humira in HS.....           Actavis talks to DOJ about resolving probe of Warner Chilcott marketing misdeeds.....           Lilly, Sanford-Burnham partner to develop new immunological therapies.....           Fibromyalgia treatment market value will crawl to $1.9bn by 2023, says GlobalData.....           Boehringer gets acceptance in Scotland for Trajenta-insulin combination to treat T2D.....           Adynxx completes enrollment in Phase II trial of AYX1 to prevent post-surgical pain.....           Cortendo to develop Antisense's ATL1103 for acromegaly.....           GlycoMimetics' GMI-1271 gets FDA orphan drug status to treat AML.....           Epirus, mAbxience enter distribution deal for infliximab biosimilar in Latin America.....           StemCells reports positive top-line results of thoracic spinal cord injury Phase I/II trial.....           Plandai gets provisional license from Uruguayan Government for R&Dof prescription cannabinoid medicines.....           D-Pharm gets final report for Phase II trial of THR-18 in acute stroke patients treated With tPA.....           Amarantus enters into cGMP manufacturing deal with Catalent Biologics for MANF.....           UPDATED: Pfizer gets friendly backing in appeal over blind rep's bid for paid driver.....           Big Pharma's a C student, rep study finds, with Bayer at the top, Novartis at bottom.....           Takeda puts screws on Orexigen for $200M do-over after 'compromised' heart trial.....           Pfizer gets friendly backing in appeal over blind rep's bid for paid driver.....           Here's a lucrative idea: Turn a drug into an orphan med, reap 6 months extra exclusivity.....           Mylan shareholders face big M&A-related taxes, especially if Teva's bid succeeds.....           Early ASCO winners? Roche and Pfizer, and to a lesser extent, BMS.....           GSK, Oxford University and Emergent begin Phase I trial of Ebola vaccine candidates.....           CEL-SCI gets approval to begin Phase III Multikine trial in Italy.....           BioCryst begins Phase I trial of BCX7353 to treat hereditary angioedema.....           AstraZeneca, MHI to screen 80,000 samples for cardiovascular and diabetes genetic traits.....           LCS Group to commercialize '813 patent and '249 application for binge eating disorder.....           ANI Pharmaceuticals takes over rights to Testosterone Gel 1%.....           Perrigo to promote Paragon BioTeck's ilast products in US.....           Sandoz to market BioQuiddity's two ready-to-use infusion products in US.....           Takeda to discontinue Phase III trial of alisertib in relapsed or refractory PTCL patients.....           Therabron's CG100 gets EMA orphan drug status to prevent bronchopulmonary dysplasia.....           Boehringer enrols first patient in Re-Circuit trial of dabigatran etexilate to treat AF.....           Bavarian Nordic reports positive results from two clinical trials of Imvamune smallpox vaccine.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Recent meetings

APS Bioequivalence of Orally Inhaled Drug Products

30 March 2015 - London

Establishing the Scientific Basis for Regulatory Acceptance of In Vitro Strategies

A well-attended one-day joint symposium organised between The Academy of Pharmaceutical Sciences (APS) and The Aerosol Society brought together many key opinion leaders from academia and industry to challenge the scientific interpretation of the guidelines for orally-inhaled drug products (OIP), in particular the links between in vitro testing and pulmonary bioavailability data.


Latest News
SME showcase at APS PharmSci 2015
FRIDAY, 1 MAY 2015
Monday 7th September . Session 1: 14.30 - 16:00 & Session 2: 16.30 - 18:00. The APS is actively seeking potential participants for the SME Showcase at APS PharmSci 2015 The SME Showcase has been running since the APS was formed and gives companies the ability to promote their innovative products, technologies and services and network with potential clients and partners. During this plenary session, successful SMEs will make a 5-10 minute presentation followed by a brief Q and A session and can also participate in a day of networking with delegates of PharmSci.. In 2014 there were 500+ delegates at PharmSci and with a strong pharmaceutical science based audience at presentations covering, medicines, diagnostics, devices and services are all valid subjects for the Showcase.. To apply for this exciting opportunity, interested organisations should contact either Bill Dawson or Geoff Davison directly with a short abstract (250 words) to be considered for selection for the programme. It is a competitive process the closing date for abstract submission is July 17th 2015 and notification of success will be by July 24th 2015.. Please submit abstracts to either Bill Dawson ( or Geoff Davison ( .
Conference Awards: 5th APS International PharmSci Conference
5th APS International PharmSci Conference: Nottingham 2015. . Conference Awards:. APS Award Lecture sponsored by AstraZeneca; Call for Nominations. The APS is pleased to announce our Call for Nominations for this years APS Award Lecture sponsored by AstraZeneca, to be delivered at APS PharmSci 2015 (September 7th- 9th) at the East Midlands Conference Centre, Nottingham.. The award will entail the following for the recipient:. To be presented at APS PharmSci 2015 with complimentary registration for the event on the day.. To deliver a 45 minute lecture within a conference plenary session. Presentation of a cheque to be donated to a charity of your choice. To be recognized as an award recipient on the APS website. Nominations Nomination should consist of a brief C.V. and a 1 page summary of contribution in fields of:. Scientific contribution: Work should be outstanding and ambassadorial in their area with an international reputation Broad scientific awareness Nominations must be made by member of the Academy. Selection Process The recipient of the award will be appointed by a Selection Committee comprising of:. Representatives of the Academy Board Representatives of the APS PharmSci 2015 Organizing Committee . GSK Emerging Scientist Award 2015; Call for Nominations. GlaxoSmithKline and the Academy of Pharmaceutical Sciences present the GSK Emerging Scientist Award and invite post-graduate and post-doctoral researchers to submit an application.. Prize The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the GSK Emerging Scientist Award Lecture on their work at APS PharmSci 2015.. Entry Criteria Entrants are welcome from researchers from across the globe in academia, industry, public service or other scientific establishments. The individual applicant should have demonstrated, through published work, a significant innovation which has the potential for application within the pharmaceutical industry.. Applicants must be within 10 years of commencing their first research position on the closing date to be eligible. Time spent in undergraduate education is excluded. Clarification on eligibility can be sought by submitting a copy of your CV to the APS at Submission Criteria Applicants are requested to submit their CV and a synopsis of their research of not more than 1000 words, focussing on its importance to the pharmaceutical industry. Diagrams and images will account for 50 words. Any references used should be cited fully using the Harvard system.. Entries should be submitted via email to Alan Ramsay at including ‘Emerging Scientist Award 2015’ in the subject field. Your email application must include your full name and postal address, a contact telephone number, your email, and your institution or organisation’s name. Entries will be judged by an APS panel.. . Timings Nominations for both awards must be received by Friday 5th June 2015 and should be sent to:. Email: Or by post to:. The Organising Committee APS PharmSci 2014 Academy of Pharmaceutical Sciences Unit Q Troon Way Business Centre Humberston Lane Leicester LE4 9HA. . Tel: 0116 274 7351. Fax: 0116 274 7365. . APS Emerging Scientist Bright Ideas Award 2015; Call for Nominations. In conjunction with this year’s conference (7th - 9th September, East Midland’s Conference Centre, Nottingham) we are pleased to announce the APS Emerging Scientists’ Bright Idea Award.. Applications are invited from students, undergraduates, recent graduates and recent post-docs to submit an innovative Bright Idea related to the Pharmaceutical Sciences with the chance for an Award of £500 as a contribution to turn the best idea into reality.. In addition to the Award the winner will be provided with the support of an experienced APS Board member to help them with their idea.. Applicants will be invited to present no-more than 2 slides on their idea at a session of the conference on Monday 7th September. There will be a vote on the ideas presented and the winner will be announced later in the day.. In the first instance you are invited to submit no more than 2 paragraphs detailing your idea and how you would spend £500 to progress it. . Last year’s entries included:. Patch with feedback to control drug delivery. Means of purifying API from trace impurities. Improving the understanding of roller compaction. Pre-filled syringes to dose paediatrics. 3D printing of drug doses -. Entries clearly marked as ‘APS Bright Idea Competition’ should be Emailed to to arrive no later than Friday 31st July 2015..
The academy of Pharmaceutical Sciences announces nomination for their awards of Fellowship and Eminent Fellowship of the Academy for 2015
The Academy of Pharmaceutical Sciences is pleased to announce nominations for two highly recognised and prestigious awards within pharmaceutical science for their members: Fellowship and Eminent Fellowship of the Academy. Fellowship of the Academy (self-nomination). The fellowship of the Academy is a science driven award and is self-nominated by members of the APS. Individuals nominating can come from all sectors where pharmaceutical scientists work, which is reflected in the criteria for eligibility. . Eligibility requirements. The nominated person must:. Have a minimum of 8 post training years in the pharmaceutical sciences. Have a minimum of 15 peer reviewed publications and /orpatents, with at least 2/3 as first or corresponding/senior author. Or have contributed substantially to the development of a medicinal product(s) , diagnostic or device. Or have contributed substantially to the development of novel technologies. Or have contributed substantially to pharmaceutical science education/training as evidenced by peer recognition- invited lectures, conference leadership, etc. and involvement in mentorship. Application process. Nominations are required to submit a CV and a one page summary detailing their contributions made using the above guidance.. Nominations must be sent to and received by the April 30th 2015. These will then be reviewed by the APS Board and applicants will be notified of the result by June 2015.. . Eminent Fellowship of the Academy (nominated by an APS member). This is an award recognising science and experience at international level with emphasis on advocacy and leadership and nominations of deserving individuals are made by APS members with two letters of support. Nomination can be from all sectors where pharmaceutical scientists work, which is reflected in the criteria for eligibility. . Eligibility requirements. The nominated person must:. Have a minimum of 10 years post qualification of involvement in the pharmaceutical sciences. Have made a significant contribution to multiple publications and /or patents. Be in a clear leadership role. Be recognised internationally for their achievements . Application process. The Nomination will be from an APS member with 2 letters of support (also from APS members). Nominations will require a two page CV and a one page career summary detailing the contributions made highlighting the criteria above. The individual being nominated would typically not be aware of their nomination.. Nominations must be sent to and received by April 30th 2015. The APS board will appoint a review panel (3) composed of Board and Advisory Board members and individuals making the nomination will be notified of the result by June 2015 for subsequent onward notification to the individual being nominated.. Past members who have won the Eminent Fellowship of the Academy can be seen on the APS website Please contact or telephone 0116 274 7531.
5th International APS PharmSci Conference 2015
7th - 9th September 2015, East Midlands Conference Centre, Nottingham. ONLINE REGISTRATION NOW OPEN The Academy of Pharmaceutical Scientist is pleased to announce that registration for the 5th International APS PharmSci Conference 2015 is now open! . The APS PharmSci 2015 Conference will showcase the best of pharmaceutical science from the UK and around the world bringing together academic and industrial institutions, providing state of the art technologies and a platform for the development of new pharmaceutical talent. The intention is to work with related partner organisations such as, JPAG, UK&ICRS, and the RPS together with the Academy's Focus Groups to deliver a high quality science programme.. For more information visit: . CALL FOR PAPERS The abstract submission process is now open. For more information on submitting an abstract, please visit us online here: The deadline for receipt of submissions is Friday, 1st May 2015. . . EXHIBITION OPPORTUNITIES Exhibition space for one of the country's largest gatherings of industrial scientists, academics, management and technicians involved in the "Science of Medicines" can now be reserved online using our interactive floorplan. . If you are interested in exhibiting please visit or contact Alan Ramsay on T: 0116 274 7351 for details or to reserve your space.. PLEASE NOTE EXHIBITION SPACES ARE LIMITED, SO DON'T DELAY AND BOOK YOUR STAND TODAY.. . SPONSORSHIP OPPORTUNITIES PharmSci 2015 provides your organisation with an ideal opportunity to increase it profile through a wide range of sponsorship opportunities. . For further details please contact Alan Ramsay on T: 0116 274 7351. .
Follow us
Upcoming Events
GSK PharmaFocus Day
3 June 2015
APS Inhaled Product Development Workshop
11 - 12 June 2015
APS 6th International PharmSci Conference 2015
7 - 9 September 2015
APS Joint Meeting with BSNM
10 September 2015
APS 20th Anniversary International Pharmaceutical Photostability Conference 2015
5 - 7 October 2015
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.